Genmab Announces Phase III Study of Daratumumab in Combination with Carfilzomib in Multiple Myeloma
Nov 10, 2016 13:28 pm UTC| Business
Company Announcement New Phase III study combining daratumumab, carfilzomib and dexamethasone in relapsed/refractory multiple myeloma – dosing expected in 2017 First study under Clinical Trial Collaboration and...
Nov 10, 2016 13:28 pm UTC| Business
VISTA, Calif., Nov. 10, 2016 -- Flux Power Holdings, Inc. (OTCQB:FLUX), a developer of lithium-ion batteries to replace lead-acid power in forklifts and other industrial equipment, reported increased sales of its LiFT...
Sun BioPharma Reports Third Quarter 2016 Results and Provides Clinical Progress Update
Nov 10, 2016 13:08 pm UTC| Business
Completed enrollment of second and third cohorts in Phase 1 clinical study of SBP-101; first-in-class proprietary compound designed specifically for pancreatic diseaseUplisted to OTCQB and secured DTC eligibility ...
Wolters Kluwer NV: Share Buyback Transaction Details November 3 - 9, 2016
Nov 10, 2016 13:05 pm UTC| Business
Alphen aan den Rijn, Netherlands, Nov. 10, 2016 -- Wolters Kluwer today reported that it has repurchased 377,871 of its own ordinary shares in the period from November 3, 2016 through November 9, 2016 for €12.4 million...
eFuture Announces Extraordinary General Meeting of Shareholders
Nov 10, 2016 13:01 pm UTC| Business
BEIJING, Nov. 10, 2016 -- eFuture HoldingInc. (“eFuture” or the “Company”) (NASDAQ:EFUT),a leading software and solution provider and a mobile business enablerto China's retail and consumer goods industries, today...
Pinnacle Entertainment Reports 2016 Third Quarter Financial Results
Nov 10, 2016 13:01 pm UTC| Business
LAS VEGAS, Nov. 10, 2016 -- Pinnacle Entertainment, Inc. (NASDAQ:PNK) today reported financial results for the third quarter ended September30, 2016. The reported financial results include 22 days of operations of the...
Nov 10, 2016 13:01 pm UTC| Business
NEWARK, Calif., Nov. 10, 2016 -- CymaBay Therapeutics, Inc. (NASDAQ:CBAY), a clinical-stage biopharmaceutical company focused on developing therapies for indications with high unmet medical need, including rare and...